# US 11,078,251 B2 · T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,251 B2
- Document ID: US11078251B2
- Status: Granted
- Kind: B2
- Application number: 15/756,091
- Filed: 2016-09-16
- Published: 2018-08-30
- Granted: 2021-08-03
- Earliest claimed: 2015-09-18
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite Paris Descartes; Centre National de la Recherche Scientifique (CNRS)
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale); Université Paris Descartes; Centre National De La Recherche Scientifique (Cnrs)
- Inventors: Roberto Mallone; Georgia Afonso; Ana Ines Lalanne; Slobodan Culina
- Web page: https://patentgrep.com/patent/US11078251B2

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 15/86: Viral vectors
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- G01N 2333/7051: T-cell receptor (TcR)-CD3 complex
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to T-cell receptors (TCR) that recognize pancreatic betacell epitopes and uses thereof for the diagnosis and treatment of diabetes.

## Claims

### Claim 1

A zinc transporter 8 (ZnT8)-specific T cell receptor (TCR) comprising an α chain and a β chain, wherein the CDR3 sequences of the β chain and the α chain comprise amino acid sequences as set forth in:
SEQ ID NO:1 and SEQ ID NO:2 respectively, or
SEQ ID NO:3 and SEQ ID NO:4 respectively, or
SEQ ID NO:5 and SEQ ID NO:6 respectively, or
SEQ ID NO:7 and SEQ ID NO:8 respectively, or
SEQ ID NO:9 and SEQ ID NO:10 or SEQ ID NO:11 respectively, or
SEQ ID NO:12 and SEQ ID NO:13 respectively, or
SEQ ID NO:14 and SEQ ID NO:15 respectively, or
SEQ ID NO:16 and SEQ ID NO:17 or SEQ ID NO:18 respectively, or
SEQ ID NO:19 and SEQ ID NO:20 respectively, or
SEQ ID NO:21 and SEQ ID NO:22 respectively, or
SEQ ID NO:23 and SEQ ID NO:24 respectively.